Invention Application
- Patent Title: TrKA Kinase Inhibitors, Compositions and Methods Thereof
-
Application No.: US15128782Application Date: 2015-03-23
-
Publication No.: US20170158698A1Publication Date: 2017-06-08
- Inventor: Helen Mitchell , Mark E. Fraley , Andrew J. Cooke , Craig A. Stump , Xu-Fang Zhang , Casey C. McComas , Kathy Schirripa , Melody McWherter , Ping Liu , Dann Parker , Chun Sing Li , Qinghua Mao
- Applicant: Helen MITCHELL , Mark E. FRALEY , Andrew J. COOKE , Craig A. STUMP , Xu-Fang ZHANG , Casey C. MCCOMAS , Kathy SCHIRRIPA , Melody MCWHERTER , Ping LIU , Dann PARKER , Chun Sing LI , Qinghua MAO , Merck Sharp & Dohme Corp.
- Applicant Address: US NJ Rahway
- Assignee: Merck Sharp & Dohme Corp.
- Current Assignee: Merck Sharp & Dohme Corp.
- Current Assignee Address: US NJ Rahway
- Priority: CNPCT/CN2014/074144 20140326
- International Application: PCT/US15/21944 WO 20150323
- Main IPC: C07D487/04
- IPC: C07D487/04 ; C07D231/40 ; C07D417/12 ; C07D401/04 ; C07D417/14 ; C07D471/04 ; C07D401/14 ; C07D403/04 ; C07D403/12 ; C07D413/12 ; C07D413/14 ; C07D277/46 ; C07D403/14
Abstract:
The present invention is directed to substituted five membered heteroaryl benzamide compounds of formula (I) (Formula (I)) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.
Public/Granted literature
- US09914736B2 TrKA kinase inhibitors, compositions and methods thereof Public/Granted day:2018-03-13
Information query
